Clinical Experience of Cefiderocol

Overview

Journal Rev Esp Quimioter

Specialty Pharmacology

Date 2022 Oct 4

PMID 36193983

Authors

M C Farinas

Affiliations

Soon will be listed here.

Abstract

Infections by antibiotic-resistant microorganisms could be considered a "stealth pandemic" that we fight daily in most hospitals. Some estimates suggest that today 700,000 deaths per year can be attributed to antimicrobial resistance. By the year 2050, it is estimated that this will increase to ten million deaths per year as a result of infections by multidrug-resistant microorganisms. In this context, the availability of antimicrobial therapy that is effective against these pathogens is essential to be able to "save the lives" of our patients. Cefiderocol, a new cephalosporin with a different mechanism of action, will be an essential treatment in many infections caused by resistant aerobic gram-negative bacteria. Cefiderocol has been used to treat patients with complicated urinary tract infections (cUTI); hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), healthcare-associated pneumonia (HAP); in patients with sepsis and bacteremia, some without an identified primary focus of infection.

Citing Articles

Cefiderocol. Summary and conclusions.

Mensa J, Barberan J Rev Esp Quimioter. 2022; 35 Suppl 2:45-47.

PMID: 36193985 PMC: 9632060. DOI: 10.37201/req/s02.07.2022.

References

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira J, Ariyasu M . Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018; 18(12):1319-1328. DOI: 10.1016/S1473-3099(18)30554-1. View

Warner N, Bartelt L, Lachiewicz A, Tompkins K, Miller M, Alby K . Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections. Clin Infect Dis. 2020; 73(7):e1754-e1757. PMC: 8678443. DOI: 10.1093/cid/ciaa1847. View

Edgeworth J, Merante D, Patel S, Young C, Jones P, Vithlani S . Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2018; 68(11):1932-1934. PMC: 6522681. DOI: 10.1093/cid/ciy963. View

Simeon S, Dortet L, Bouchand F, Roux A, Bonnin R, Duran C . Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint Infection Due to Extensively Drug-Resistant . Microorganisms. 2020; 8(8). PMC: 7464826. DOI: 10.3390/microorganisms8081236. View

Bavaro D, Romanelli F, Stolfa S, Belati A, Diella L, Ronga L . Recurrent neurosurgical site infection by extensively drug-resistant treated with cefiderocol: a case report and literature review. Infect Dis (Lond). 2020; 53(3):206-211. DOI: 10.1080/23744235.2020.1856921. View

Alamarat Z, Babic J, Tran T, Wootton S, Dinh A, Miller W . Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient. Antimicrob Agents Chemother. 2019; 64(4). PMC: 7179260. DOI: 10.1128/AAC.01872-19. View

Trecarichi E, Quirino A, Scaglione V, Longhini F, Garofalo E, Bruni A . Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother. 2019; 74(11):3399-3401. DOI: 10.1093/jac/dkz318. View

Contreras D, Fitzwater S, Nanayakkara D, Schaenman J, Aldrovandi G, Garner O . Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing Klebsiella pneumoniae in a Kidney Transplant Patient. Antimicrob Agents Chemother. 2019; 64(4). PMC: 7179284. DOI: 10.1128/AAC.00948-19. View

Hsueh S, Lee Y, Huang Y, Liao C, Tsuji M, Hsueh P . In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with.... J Antimicrob Chemother. 2018; 74(2):380-386. DOI: 10.1093/jac/dky425. View

10.

Wunderink R, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye K . Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2020; 21(2):213-225. DOI: 10.1016/S1473-3099(20)30731-3. View

11.

Stevens R, Clancy M . Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report. Pharmacotherapy. 2019; 39(11):1113-1118. DOI: 10.1002/phar.2334. View

12.

McCarthy M . Cefiderocol to treat complicated urinary tract infection. Drugs Today (Barc). 2020; 56(3):177-184. DOI: 10.1358/dot.2020.56.3.3118466. View

13.

Bavaro D, Belati A, Diella L, Stufano M, Romanelli F, Scalone L . Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Antibiotics (Basel). 2021; 10(6). PMC: 8227820. DOI: 10.3390/antibiotics10060652. View

14.

Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C . Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis. 2020; 72(11):2021-2024. DOI: 10.1093/cid/ciaa1410. View

15.

Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R . Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3.... Lancet Infect Dis. 2020; 21(2):226-240. DOI: 10.1016/S1473-3099(20)30796-9. View

16.

Zingg S, Nicoletti G, Kuster S, Junker M, Widmer A, Egli A . Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. Open Forum Infect Dis. 2020; 7(6):ofaa185. PMC: 7284008. DOI: 10.1093/ofid/ofaa185. View

17.

Portsmouth S, Echols R, Nagata T . Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis. 2018; 19(1):23-24. DOI: 10.1016/S1473-3099(18)30721-7. View

18.

Oliva A, Ceccarelli G, De Angelis M, Sacco F, Miele M, Mastroianni C . Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2020; 23:292-296. DOI: 10.1016/j.jgar.2020.09.019. View

19.

Dagher M, Ruffin F, Marshall S, Taracila M, Bonomo R, Reilly R . Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Osteomyelitis With Cefiderocol. Open Forum Infect Dis. 2020; 7(5):ofaa150. PMC: 7252278. DOI: 10.1093/ofid/ofaa150. View